← Back to Screener
Johnson & Johnson (JNJ)
Price$230.69
Favorite Metrics
Price vs S&P 500 (26W)13.95%
Price vs S&P 500 (4W)-10.15%
Market Capitalization$560.47B
P/E Ratio (Annual)20.91x
Indicated Dividend Yield (Annual)2.32%
All Metrics
P/CF (Annual)22.85x
Book Value / Share (Quarterly)$33.86
P/TBV (Annual)16.06x
Indicated Dividend (Annual)$5.20
Revenue Growth (3Y)5.60%
Cash Flow / Share (Quarterly)$8.18
Payout Ratio (TTM)46.19%
Price vs S&P 500 (YTD)7.54%
Gross Margin (TTM)67.95%
Net Profit Margin (TTM)21.83%
EPS (TTM)$8.65
10-Day Avg Trading Volume7.85M
EPS Excl Extra (TTM)$8.65
Revenue Growth (5Y)2.67%
EPS (Annual)$11.03
Dividend / Share (Annual)$5.14
ROI (Annual)20.70%
Gross Margin (Annual)67.98%
Net Profit Margin (5Y Avg)26.91%
Cash / Share (Quarterly)$8.35
P/E Basic Excl Extra (TTM)26.64x
Revenue Growth QoQ (YoY)9.91%
EPS Growth (5Y)14.90%
P/E Normalized (Annual)20.91x
ROA (Last FY)13.46%
Revenue Growth TTM (YoY)7.87%
EBITD / Share (TTM)$12.41
ROE (5Y Avg)31.04%
Operating Margin (TTM)25.88%
Cash Flow / Share (Annual)$8.18
P/B Ratio6.87x
P/B Ratio (Quarterly)6.13x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)6.36x
Net Interest Coverage (TTM)34.01x
ROA (TTM)13.76%
EPS Growth QoQ (YoY)-52.82%
EV / EBITDA (TTM)15.17x
EPS Incl Extra (Annual)$11.03
Current Ratio (Annual)1.03x
Quick Ratio (Quarterly)0.69x
3-Month Avg Trading Volume8.51M
52-Week Price Return46.50%
EV / Free Cash Flow (Annual)30.41x
P/E Incl Extra (TTM)26.64x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$12.93
P/S Ratio (Annual)5.95x
Asset Turnover (Annual)0.47x
52-Week High$251.71
Operating Margin (5Y Avg)23.93%
EPS Excl Extra (Annual)$11.03
CapEx CAGR (5Y)7.62%
Tangible BV CAGR (5Y)25.82%
26-Week Price Return20.84%
Quick Ratio (Annual)0.69x
13-Week Price Return5.06%
Total Debt / Equity (Annual)0.59x
Current Ratio (Quarterly)1.03x
Enterprise Value$599,113.25
Revenue / Share Growth (5Y)4.63%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)7.10%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.27x
Pretax Margin (Annual)34.59%
Cash / Share (Annual)$8.35
3-Month Return Std Dev14.99%
Gross Margin (5Y Avg)69.16%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)11.32%
EBITDA Interim CAGR (5Y)-8.61%
ROE (Last FY)32.87%
Net Interest Coverage (Annual)35.19x
EPS Basic Excl Extra (Annual)$11.03
P/FCF (TTM)28.45x
Receivables Turnover (TTM)5.88x
EV / Free Cash Flow (TTM)30.41x
Total Debt / Equity (Quarterly)0.59x
EPS Incl Extra (TTM)$8.65
Receivables Turnover (Annual)5.88x
ROI (TTM)20.85%
Dividend Growth Rate (5Y)7.68%
P/S Ratio (TTM)5.82x
Pretax Margin (5Y Avg)23.93%
Revenue / Share (Annual)$38.77
Tangible BV / Share (Annual)$12.93
Forward P/E19.91x
Free OCF CAGR (5Y)-0.49%
Price vs S&P 500 (52W)11.87%
P/E Ratio (TTM)26.64x
EPS Growth TTM (YoY)-3.89%
Year-to-Date Return11.47%
5-Day Price Return-3.92%
EPS Normalized (Annual)$11.03
ROA (5Y Avg)12.66%
Net Profit Margin (Annual)28.46%
Month-to-Date Return-5.63%
Cash Flow / Share (TTM)$7.61
EBITD / Share (Annual)$16.40
EPS Growth (3Y)17.88%
Operating Margin (Annual)34.59%
LT Debt / Equity (Annual)0.48x
P/CF (TTM)22.85x
ROI (5Y Avg)20.86%
P/E Excl Extra (TTM)26.64x
LT Debt / Equity (Quarterly)0.48x
EPS Basic Excl Extra (TTM)$8.65
P/TBV (Quarterly)16.06x
Payout Ratio (Annual)46.19%
P/B Ratio (Annual)6.13x
Dividend / Share (TTM)$5.14
Inventory Turnover (TTM)2.27x
Pretax Margin (TTM)25.88%
Book Value / Share (Annual)$33.86
Price vs S&P 500 (13W)2.68%
Net Margin Growth (5Y)9.82%
Dividend Yield (TTM)2.21%
Beta0.28x
P/FCF (Annual)28.45x
Revenue / Share (TTM)$39.41
ROE (TTM)33.78%
52-Week Low$146.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.75
3.78
3.78
3.81
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share) | 1.40x | 69.14% | 72.55% | -8.08% | $47.99 |
About
Johnson & Johnson is a leading global healthcare company with two core divisions: innovative medicines and medical devices. Following the 2023 divestment of its consumer health business and recent portfolio restructuring, the company concentrates on high-growth therapeutic areas including immunology, oncology, and neurology. Over half of revenue is generated in the United States, with the remainder derived from international markets.